Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib

Leukemia. 2014 Jun;28(6):1363-5. doi: 10.1038/leu.2014.39. Epub 2014 Jan 21.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / complications*
  • Breast Neoplasms / therapy
  • Carrier Proteins / genetics*
  • Combined Modality Therapy
  • Drug Resistance, Neoplasm / drug effects
  • Erythroid Cells / drug effects
  • Erythroid Cells / metabolism
  • Erythroid Cells / pathology
  • Female
  • Granulocytes / drug effects
  • Granulocytes / metabolism
  • Granulocytes / pathology
  • Humans
  • Hydroxyurea / therapeutic use
  • In Vitro Techniques
  • Janus Kinase 2 / antagonists & inhibitors*
  • Leukemia, Neutrophilic, Chronic / drug therapy
  • Leukemia, Neutrophilic, Chronic / etiology*
  • Leukemia, Neutrophilic, Chronic / pathology
  • Mutation / genetics*
  • Nitriles
  • Nuclear Proteins / genetics*
  • Prognosis
  • Pyrazoles / therapeutic use*
  • Pyrimidines
  • Receptors, Colony-Stimulating Factor / genetics*
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • CSF3R protein, human
  • Carrier Proteins
  • Nitriles
  • Nuclear Proteins
  • Pyrazoles
  • Pyrimidines
  • Receptors, Colony-Stimulating Factor
  • SETBP1 protein, human
  • ruxolitinib
  • JAK2 protein, human
  • Janus Kinase 2
  • Hydroxyurea